Eli Lilly and French biotech Adocia have reached an agreement for a worldwide licensing partnership to develop an ultra-rapid insulin to treat patients with type 1 and type 2 diabetes. The deal will strengthen the position of Eli Lilly into the very competitive diabete’s market.

The product is currently in early-stage phase Ib studies and aims to control glucose levels better during and after meals. According to the companies, Adocia will receive an upfront fee of $50 million, potential future payments of up to $280 million if the product reaches certain development and regulatory milestones, and sales milestones of up to $240 million.

Lilly will also pay royalties on sales of the drug, if approved, and reimburse Adocia for some of its research and development expenses, for an unspecified amount.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here